Company news
Arno Therapeutics Inc (OTC:ARNI) news
Arno Therapeutics Inc news releases on 6ix. Latest, Dec 22, 2017: Arno Therapeutics Announces Plans to Dissolve
Press releases & updates
Arno Therapeutics Announces Plans to Dissolve
December 22, 2017
Arno Therapeutics Announces Plan to Deregister its Common Stock
March 28, 2017
Arno Therapeutics Announces Update to Onapristone Prostate Cancer Development Program
January 4, 2017
Arno Therapeutics Announces Cancellation of Special Meeting of Stockholders
December 21, 2016
Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update
November 14, 2016
Arno Therapeutics Reports Second Quarter 2016 Financial and Business Update
August 22, 2016
Arno Completes $2.8 Million Private Placement
August 22, 2016
Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
May 16, 2016
UCLA's Dr. Stuart Holden Interviewed by The Life Sciences Report
April 21, 2016
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA®
April 19, 2016
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 30, 2016
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II
March 21, 2016
Arno Therapeutics Completes $7.4 Million Common Stock Financing
January 13, 2016
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update
November 16, 2015
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis
October 29, 2015
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
October 21, 2015
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
September 25, 2015
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections
September 24, 2015
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
September 19, 2015
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
September 19, 2015
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
September 14, 2015
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference
September 1, 2015
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
August 18, 2015
Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update
August 14, 2015
Arno Therapeutics Announces Issuance of First Onapristone Patent
June 4, 2015
Arno Therapeutics Announces Cooperative Research and Development Agreement With US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
June 3, 2015
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
May 28, 2015
Arno Therapeutics Reports First Quarter 2015 Financial and Business Update
May 15, 2015
Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
May 14, 2015
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015
May 13, 2015
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
May 7, 2015
Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
April 30, 2015
Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
April 29, 2015
Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015
April 21, 2015
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
April 13, 2015
Arno Therapeutics Inc.'s CEO Alexander Zukiwski Interviewed by The Life Sciences Report
April 9, 2015
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update
March 31, 2015
New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology
March 24, 2015
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
January 8, 2015
OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 2
January 2, 2015